Market open
ADC Therapeutics/$ADCT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Ticker
$ADCT
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Epalinges, Switzerland
Employees
274
Website
ADC Therapeutics Metrics
BasicAdvanced
$160M
-
-$2.32
1.60
-
Price and volume
Market cap
$160M
Beta
1.6
52-week high
$6.04
52-week low
$1.61
Average daily volume
772K
Financial strength
Current ratio
4.92
Quick ratio
4.408
Long term debt to equity
-259.208
Total debt to equity
-264.267
Interest coverage (TTM)
-2.70%
Management effectiveness
Return on assets (TTM)
-21.17%
Return on equity (TTM)
187.64%
Valuation
Price to revenue (TTM)
2.132
Price to book
-0.93
Price to tangible book (TTM)
-0.93
Price to free cash flow (TTM)
-1.119
Growth
Revenue change (TTM)
-42.30%
Earnings per share change (TTM)
4.52%
3-year revenue growth (CAGR)
61.12%
3-year earnings per share growth (CAGR)
-10.86%
What the Analysts think about ADC Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ADC Therapeutics stock.
ADC Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADC Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ADC Therapeutics stock?
ADC Therapeutics (ADCT) has a market cap of $160M as of January 30, 2025.
What is the P/E ratio for ADC Therapeutics stock?
The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of January 30, 2025.
Does ADC Therapeutics stock pay dividends?
No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next ADC Therapeutics dividend payment date?
ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.
What is the beta indicator for ADC Therapeutics?
ADC Therapeutics (ADCT) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.